Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis

Completed · Not applicable

Conditions studied: Cystic Fibrosis, Mucociliary Clearance Defect

In brief

This is a pilot study investigating the effectiveness and clinical efficacy of airway clearance therapy (ACT) in cystic fibrosis (CF). Enrolled subjects will undergo measurements of mucociliary clearance (MCC) and exhaled biomarkers at baseline and after 3 different forms of ACT: high frequency chest wall oscillatory vest, oscillatory positive expiratory pressure device, and whole-body vibration.

Key facts

Study ID

NCT03078127

Run by

University of North Carolina, Chapel Hill

People needed

10

Starts

2017-02-01

Expected to finish

2018-01-10

Last updated by the study team

2019-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults with confirmed diagnosis of cystic fibrosis aged 18 years and older.

You may not qualify if…

• Pregnant or lactating women,
• Individuals with severe lung disease (FEV1 <30%), or with exacerbations of lung disease requiring antibiotics or medication change within four weeks prior to enrolment.
• Individuals unable to use vest-based HFCWO, OPEP device, or who require oxygen supplementation at rest.
• Individuals with significant balance or gait impairment preventing them from tolerating being positioned on a vibrating platform.

Where it is running

• Marsico Clinical Research Center — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.